Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02016729 · ClinicalTrials.gov registry record · Phase 1
A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia
A Phase 1 study of Cancer and Acute Myeloid Leukemia, sponsored by Kartos Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 5
- Study locations
NCT02016729 is a Phase 1 study of Cancer and Acute Myeloid Leukemia that has completed, run by Kartos Therapeutics. The registered enrollment target is 36 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT02016729, a Phase 1 study of Cancer and Acute Myeloid Leukemia, has completed, sponsored by Kartos Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 5
- Study locations
Study Summary
Open-label, sequential dose escalation and expansion study of AMG 232 in subjects with acute myeloid leukemia.
Conditions Studied
Interventions
- DRUG Trametinib
- DRUG AMG 232
Study Locations (5)
Alabama
- Research Site - Birmingham
New York
- Research Site - Buffalo
North Carolina
- Research Site - Charlotte
Utah
- Research Site - Salt Lake City
Washington
- Research Site - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2014-04-01 |
| Est. Completion | 2017-07-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02016729
The ClinicalTrials.gov registry entry for NCT02016729 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Kartos Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Cancer appearing as the primary indexed condition, and to 2 interventions - of which Trametinib is the first listed.
NCT02016729 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Alabama, New York, North Carolina.
Frequently Asked Questions
What is clinical trial NCT02016729 about?
NCT02016729 is a clinical study titled "A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia". Open-label, sequential dose escalation and expansion study of AMG 232 in subjects with acute myeloid leukemia.
What is the current status of trial NCT02016729?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2014-04-01. Estimated completion is 2017-07-31.
What conditions does trial NCT02016729 study?
This clinical trial studies the following conditions: Cancer, Acute Myeloid Leukemia, Oncology, Oncology Patients, Advanced Malignancy.
What interventions are being tested in trial NCT02016729?
The interventions under investigation include: Trametinib (DRUG), AMG 232 (DRUG).
Who is sponsoring clinical trial NCT02016729?
This trial is sponsored by Kartos Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02016729 being conducted?
This trial has 5 study locations across Alabama, New York, North Carolina, Utah, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.